Drug intelligence / Profile preview

ORIC-944 + apalutamide

Development stage: Unknown
Lead developer: ORIC Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

ORIC-944 + apalutamide is an investigational combination therapy under clinical evaluation for metastatic castration-resistant prostate cancer (mCRPC). ORIC-944 is a potent, highly selective, allosteric, orally bioavailable small molecule inhibitor of the polycomb repressive complex 2 (PRC2), acting via the embryonic ectoderm development (EED) subunit. Apalutamide is a well-established androgen receptor (AR) inhibitor. This combination is designed to overcome resistance to AR pathway inhibition by simultaneously inhibiting PRC2-driven epigenetic mechanisms and directly blocking AR signaling. Early-phase clinical trials have demonstrated promising PSA response rates and a safety profile compatible with long-term dosing[1][2][5].

Brand names: Erleada
Other names: ORIC-944 + apalutamideErleada + ORIC-944

Targets

EED (Embryonic ectoderm development protein)AR (Adrenergic receptors)

Beyond the preview

Go deeper on ORIC-944 + apalutamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORIC-944 + apalutamide.

Explore the full profile